Compare MobilEye Global Inc (MBLY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Sanofi SA — how do they compare? MobilEye Global Inc trades at $8.84 (market cap $7.54B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 13.8× MobilEye Global Inc's market cap, and Sanofi SA pays a 5.55% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.
| MBLY | SNY | |
|---|---|---|
Market Cap | $7.54B | $104.30B |
Sector | Technology | Health |
52-Week High | $15.54 | $52.34 |
52-Week Low | $6.56 | $41.33 |
Enterprise Value | $6.10B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global Inc. (MBLY) trades at $8.77, up 0.23% on the day, with a bullish technical signal driven by moving averages. The stock shows strong earnings beats in recent quarters, with Q2 2026 EPS of $0.19 surpassing expectations, but faces fundamental challenges with a net income margin of -201.49% in 2026. Recent news highlights CEO transition and expanded partnerships, such as the Stellantis ADAS supply deal announced July 21, 2026.
The outlook is mixed: analyst consensus is bullish with a $11.40 price target (61.54% buy ratings), but high valuation (EV/EBITDA 43.25) and profitability risks persist. Investment opportunity lies in autonomous driving growth, while key risks include leadership uncertainty and competitive pressures.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
